10-K: Cyclo Therapeutics, Inc. Details Securities and Anti-Takeover Measures in Annual 10-K Filing

Cyclo Therapeutics, Inc.'s annual 10-K filing provides a detailed overview of the company's securities, including common stock and warrants, as well as anti-takeover provisions and recent business activities.

Summary

• Cyclo Therapeutics, Inc. has filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.
• The company has 250,000,000 authorized shares of common stock and 5,000,000 authorized shares of preferred stock, with no preferred stock currently issued.
• As of December 31, 2023, there were 2,303,000 outstanding warrants to purchase common stock at an exercise price of $5.00 per share, expiring on December 11, 2025.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol CYTH, and its warrants trade under the symbol CYTHW.
• The document outlines anti-takeover provisions in the company's articles of incorporation and bylaws, as well as Nevada state laws that could make acquisitions more difficult.
• The company completed a merger with Applied Molecular Transport, Inc. on December 27, 2023, in an all-stock transaction.
• Cyclo Therapeutics is a clinical-stage biotechnology company focused on developing cyclodextrin-based products for neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC).
• The company estimates the total addressable annual market for treating NPC with Trappsol Cyclo to be approximately $550 million.
• The company is also exploring the use of cyclodextrins in the treatment of Alzheimers disease and received a notice of allowance for a patent application related to this.
• Research and development expenses were approximately $14.2 million in 2023, compared to $9 million in 2022.
• The company's operations used approximately $16.2 million in cash in 2023, and it had a cash balance of approximately $9.2 million at the end of the year.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern due to recurring losses and a significant accumulated deficit.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as clinical progress and patent allowances, the significant losses, going concern warning, and need for additional capital raise concerns. The overall sentiment is cautiously negative.

Positives

• The company has orphan drug designation for Trappsol Cyclo in both the U.S. and Europe, providing market exclusivity upon approval.
• The company has completed Phase I and Phase I/II clinical studies for Trappsol Cyclo, showing promising results in treating NPC.
• The company has commenced enrollment in a pivotal Phase III study for Trappsol Cyclo.
• The company has received a notice of allowance for a patent application for the treatment of Alzheimers disease.
• The company has a legacy fine chemical business that generates revenue, although the focus is now on biopharmaceuticals.
• The company has a strong intellectual property position with trademarks for Trappsol and Aquaplex.

Negatives

• The company has incurred significant net losses, with $20.1 million in 2023 and $15.5 million in 2022.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company is dependent on the success of its Trappsol Cyclo product, which may not receive regulatory approval.
• The company faces competition from other entities developing treatments for NPC.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or quality issues.
• The company has a limited number of customers that account for a substantial portion of its revenue.
• The company is subject to increasing government regulation and reform, including price controls and reimbursement pressures.

Risks

• The company's future profitability is uncertain, and it may not be able to sustain profitability if achieved.
• The company will need additional capital to fund its operations, and there is no guarantee that it will be available on acceptable terms.
• The company is dependent on the success of Trappsol Cyclo, which may not receive regulatory approval.
• Clinical trials may not support product claims or may result in the discovery of adverse side effects.
• The company relies on third parties for research, clinical trials, and manufacturing, which could lead to delays or quality issues.
• The company faces competition from well-funded companies to treat NPC.
• The company's business and operations could suffer in the event of computer system failures or security breaches.
• The company's intellectual property rights may be inadequate, and it may be susceptible to intellectual property suits.
• The company is subject to increasing government regulation and reform, including price controls and reimbursement pressures.
• The company is dependent on certain third-party suppliers for its fine chemical business.
• The company may be negatively affected by currency exchange rate fluctuations.
• The market price of the company's common stock may be highly volatile, and investors could lose all or part of their investment.
• The company's failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a de-listing of its securities.

Future Outlook

The company expects to continue to raise additional capital through the sale of its securities to fund the development of its drug product candidates through clinical development, manufacturing, and commercialization. The company believes it will have sufficient cash to meet its anticipated operating costs and capital expenditure requirements for at least the next six months.

Management Comments

• Management believes that Trappsol Cyclo can function like the NPC1 protein, allowing cholesterol and other lipids to be moved normally through cells.
• Management believes that the company may be the only company with a drug candidate that treats both the systemic and neurological manifestations of NPC.
• Management believes that the company's clinical progress, close connections with patient advocacy groups, and the fact that it has a finished product currently in use in human patients give it a competitive advantage.
• Management believes that the company's relationships and market knowledge provide significant business advantages in the cyclodextrin industry.

Industry Context

The company operates in the biotechnology industry, specifically focusing on rare diseases like NPC and neurodegenerative diseases like Alzheimers. The company faces competition from other pharmaceutical and biotechnology companies, as well as governmental institutions, that are also working on treatments for these conditions. The company's focus on cyclodextrin-based therapies is a unique approach in the industry.

Comparison to Industry Standards

• The company's reliance on third-party manufacturers and CROs is common in the biotechnology industry, but it also introduces risks related to quality and timelines.
• The company's research and development expenses are significant, which is typical for a clinical-stage biotechnology company.
• The company's cash burn rate is high, which is also common for companies in this stage of development.
• The company's need for additional capital is a common challenge for clinical-stage biotechnology companies, and its reliance on equity financing is a typical approach.
• The company's focus on orphan drug designation is a common strategy for companies developing treatments for rare diseases, as it provides market exclusivity and other benefits.
• The company's anti-takeover provisions are not uncommon for publicly traded companies, but they can make acquisitions more difficult.
• The company's financial results are not directly comparable to larger, more established pharmaceutical companies, as it is still in the clinical development phase and has not yet generated significant revenue from product sales.
• The company's reliance on a small number of customers for its legacy fine chemical business is a risk that is not uncommon for smaller companies.

Management Changes

Corporate Governance

Legal Proceedings

• In December 2023, two lawsuits were filed against AMTI in connection with the Merger. The Company has accrued an estimate of potential liability based on the best information available.
• The company is a party to claims and legal proceedings arising in the ordinary course of business.

Related Party Transactions

• The company has a consulting agreement with C.E. Rick Strattan, a director and former CEO.
• The company employs Joshua M. Fine, the son of the CEO, as its Chief Financial Officer.
• The company employs Kevin J. Strattan, the son of C.E. Rick Strattan, as its Vice President, Finance Compensation.
• The company employs Corey E. Strattan, the daughter-in-law of C.E. Rick Strattan, as a documentation specialist and logistics coordinator.
• Certain directors and officers participated in private placements of the company's securities.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's financial challenges.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers of the company's fine chemical business may be affected by changes in the company's focus and operations.
• Patients with NPC and Alzheimers disease may benefit from the company's development of new treatments, but there is no guarantee of success.
• Creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company will continue its ongoing Phase III clinical trial for Trappsol Cyclo in the treatment of NPC.
• The company will continue to explore the use of cyclodextrins in the treatment of Alzheimers disease.
• The company will continue to seek regulatory approvals for Trappsol Cyclo.
• The company will continue to raise additional capital to fund its operations.
• The company will continue to operate its legacy fine chemical business.

Key Dates

Keywords

Cyclo Therapeutics, Trappsol Cyclo, Niemann-Pick Type C disease, NPC, Alzheimers disease, cyclodextrins, biotechnology, clinical trials, orphan drug, pharmaceutical, warrants, securities, merger, anti-takeover, regulatory approval